Database analysis reveals low clinical trial volume and high failure rates for Alzheimer's therapeutics, highlighting an urgent need to support the drug-development ecosystem.
The Clinicaltrials.gov database demonstrates that relatively few clinical trials are undertaken for AD therapeutics, considering the magnitude of the problem. The success rate for advancing from one phase to another is low, and the number of compounds progressing to regulatory review is among the lowest found in any therapeutic area. The AD drug-development ecosystem requires support.
No takes yet. Share an insight, caveat, or question.
Cummings et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: